F
Florence Le Maulf
Researcher at Boehringer Ingelheim
Publications - 9
Citations - 4161
Florence Le Maulf is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Nintedanib & FEV1/FVC ratio. The author has an hindex of 7, co-authored 9 publications receiving 3384 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more
TL;DR: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintinganib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.
Journal ArticleDOI
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman,Ajay K. Kakkar,Samuel Z. Goldhaber,Sebastian Schellong,Henry Eriksson,Patrick Mismetti,Anita Vedel Christiansen,Jeffrey Friedman,Florence Le Maulf,Nuala Peter,Clive Kearon +10 more
TL;DR: Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE.
Journal ArticleDOI
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Ganesh Raghu,Athol U. Wells,Andrew G. Nicholson,Luca Richeldi,Kevin R. Flaherty,Florence Le Maulf,Susanne Stowasser,Rozsa Schlenker-Herceg,David M. Hansell +8 more
TL;DR: Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing onHRCT and/or confirmation of UIP by biopsy.
Journal ArticleDOI
Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R. Flaherty,Kevin K. Brown,Athol U. Wells,Emmanuelle Clerisme-Beaty,Harold R. Collard,Vincent Cottin,Anand Devaraj,Yoshikazu Inoue,Florence Le Maulf,Luca Richeldi,Hendrik Schmidt,Simon L.F. Walsh,William Mezzanotte,Rozsa Schlenker-Herceg +13 more
TL;DR: The main secondary endpoints are the absolute change from baseline in King’s Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks.
Journal ArticleDOI
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Luca Richeldi,Vincent Cottin,Kevin R. Flaherty,Martin Kolb,Yoshikazu Inoue,Ganesh Raghu,Hiroyuki Taniguchi,David M. Hansell,Andrew G. Nicholson,Florence Le Maulf,Susanne Stowasser,Harold R. Collard +11 more
TL;DR: The INPULSIS™ trials will determine the efficacy of nintedanib in patients with IPF, including its impact on disease progression as defined by decline in FVC, acute exacerbations and health-related quality of life.